Dr. Saad on Radium-223 for Prostate Cancer

Video

Fred Saad, MD, professor and chief of Urology, Director of Genitourinary Oncology at the University of Montreal Hospital Centers, discusses radium-223 dichloride (Xofigo) for patients with prostate cancer.

Fred Saad, MD, professor and chief of Urology, Director of Genitourinary Oncology at the University of Montreal Hospital Centers, discusses radium-223 dichloride (Xofigo) for patients with prostate cancer.

According to a large phase III study, radium-223 improved overall survival and reduced the risk of symptomatic skeletal complications, which led to the FDA approval of radium-223 as a treatment for patients with prostate cancer.

Saad is involved in a trial that compared radium-223 with other treatments that were not available during the pivotal phase III study. Radium-223 was compared with drugs such as abiraterone acetate (Zytiga), enzalutamide (Xtandi), and denosumab (Xgeva). That study showed that patients do well with radium-223, especially if they can get all 6 cycles of therapy, Saad explains.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD